NOTE 16 – SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2020
Subsequent Events [Abstract]
NOTE 16 – SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS On August 5, 2020, we entered into Amendment No. 5 to the Financing Agreement (the “Amendment”) with the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors. The Amendment adjusts the covenant in the Financing Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant is effective beginning with the fiscal quarter ending December 31, 2020. In connection with the Amendment and in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of approximately 4,750,000 shares of Common Stock with an exercise price of $1.58 per share and a ten year term (the “Lender Warrants”). The Lender Warrants were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, and no registration rights were issued. The Lender Warrants do not have anti-dilution protection, other than for customary stock splits and similar transactions.

NOTE 16 – SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2020

NOTE 16 – SUBSEQUENT EVENTS

On August 5, 2020, we entered into Amendment No. 5 to the Financing Agreement (the “Amendment”) with the Administrative Agent, various lenders from time to time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors. The Amendment adjusts the covenant in the Financing Agreement regarding our achievement of minimum consolidated net revenue attributable to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant is effective beginning with the fiscal quarter ending December 31, 2020. In connection with the Amendment and in lieu of a cash amendment fee, we issued to the Administrative Agent and the lenders under the Financing Agreement warrants to purchase an aggregate of approximately 4,750,000 shares of Common Stock with an exercise price of $1.58 per share and a ten year term (the “Lender Warrants”). The Lender Warrants were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, and no registration rights were issued. The Lender Warrants do not have anti-dilution protection, other than for customary stock splits and similar transactions.